INDOLE CARBINOL IS A MULTITARGETED THERAPY OPTION FOR CYCLIC MASTODYNIA

  • Authors: KISELEV V.I1, SMETNIK V.P2, SUTURINA L.V3, SELIVANOV S.P4, RUDAKOVA E.B5, RAKHMATULLINA I.R6, ANDREYEVA E.N7, FADEYEVA N.I8, KHASANOV R.S.9, KULAGINA N.V10, ROZHKOVA N.I11, ARTYMUK N.V12, GAVISOVA A.A2, MUIZHNEK E.L13, KUZNETSOV I.N14, DRUKH V.M15
  • Affiliations:
    1. National Research Center "Kurchatov Institute"
    2. Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia Federation
    3. Research Centre for Family Health and Human Reproduction Problems, Siberian Branch, Russian Academy of Medical Sciences
    4. Therapeutic and Diagnostic Center, Tomsk 5Omsk State Medical Academy, Ministry of Health of Russia Federation
    5. Omsk State Medical Academy, Ministry of Health of Russia Federation
    6. Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan, Ufa 7Endocrinology Research Center, Ministry of Health of the Russian Federation
    7. Endocrinology Research Center, Ministry of Health of the Russian Federation
    8. Altai State Medical University, Ministry of Health of Russia Federation
    9. Republican Clinical Oncology Dispensary, Ministry of Health of Russia of Tatarstan
    10. I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia Federation
    11. Russian X-ray Radiology Research Center, Ministry of Health of Russia Federation
    12. Kemerovo State Medical Academy, Ministry of Health of Russia Federation
    13. ZAO "MiraxBioPharma"
    14. A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia Federation
    15. ZAO «IlmixGroup»
  • Issue: No 7 (2013)
  • Pages: 56-62
  • Section: Articles
  • URL: https://journals.eco-vector.com/0300-9092/article/view/247021
  • ID: 247021

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To determine the efficacy of a new indole carbinol-based medication (indinol forto) in treating cyclic mastalgia (mastodynia) and benign breast dysplasia (fibrocystic mastopathy). Subject and methods. A multicenter randomized double-blind placebo-controlled trial was conducted in 156 patients who received 400 mg/day of indole carbinol or placebo during 6 menstrual cycles. Results. According to the breast pain criterion, the therapeutic effectiveness was significantly higher in the indinol forto group than in the placebo group (84.4% versus 53.3%; p = 0.002). After 6 months of therapy pain was relieved or gone in 85.1% of the patients in the mastopathy subgroup (50.0% in the placebo group; p = 0.004). The indinol forto group showed a decrease in the size of cysts in 18% of the patients, its stabilization and growth in 71 and 11%, respectively. In the placebo group, there was stabilization of cyst sizes in 75% of the patients and their growth in 25%; no reduction in cyst sizes was noted. It was also ascertained that in the indinol forto group, there was an increment of plasma sex-steroid-binding globulin levels and an increase in the ratio of urinary estrogen metabolites (2-hydroxyestrone/16α-hydroxyestrone). Conclusion. Indinol forto may be recommended for the treatment of patients with both cyclic mastalgia (mastodynia) and mastopathy.

Full Text

Restricted Access

About the authors

V. I KISELEV

National Research Center "Kurchatov Institute"

Email: vkis10@mail.ru

V. P SMETNIK

Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia Federation

Email: verasmetnik@mail.ru

L. V SUTURINA

Research Centre for Family Health and Human Reproduction Problems, Siberian Branch, Russian Academy of Medical Sciences

Email: lsuturina@mail.ru
Irkutsk

S. P SELIVANOV

Therapeutic and Diagnostic Center, Tomsk 5Omsk State Medical Academy, Ministry of Health of Russia Federation

Email: am@am.tom.ru
Omsk

E. B RUDAKOVA

Omsk State Medical Academy, Ministry of Health of Russia Federation

Email: doctor_rudakova@mail.ru
Omsk

I. R RAKHMATULLINA

Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Bashkortostan, Ufa 7Endocrinology Research Center, Ministry of Health of the Russian Federation

Email: rahmatullina@rambler.ru

E. N ANDREYEVA

Endocrinology Research Center, Ministry of Health of the Russian Federation

Email: endogin@mail.ru

N. I FADEYEVA

Altai State Medical University, Ministry of Health of Russia Federation

Email: nat2fad@hotmail.com
Barnaul

R. SH KHASANOV

Republican Clinical Oncology Dispensary, Ministry of Health of Russia of Tatarstan

Email: rkod.mzrt@tatar.ru
Kazan

N. V KULAGINA

I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia Federation

Email: dr.Kulagina@mail.ru
Saint Petersburg

N. I ROZHKOVA

Russian X-ray Radiology Research Center, Ministry of Health of Russia Federation

Email: rozhkova@rncrr.ru

N. V ARTYMUK

Kemerovo State Medical Academy, Ministry of Health of Russia Federation

Email: artymuk@kemtel.ru

A. A GAVISOVA

Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia Federation

Email: gavialla@yandex.ru

E. L MUIZHNEK

ZAO "MiraxBioPharma"

Email: MuyzhnekEL@ilmixgroup.ru

I. N KUZNETSOV

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia Federation

Email: kuznetsovin@ilmixgroup.ru

V. M DRUKH

ZAO «IlmixGroup»

Email: DruhVM@ilmixgroup.ru

References

  1. Bradlow H.L., Michnovicz J.J., Halper M., Miller D.G., Wong G.Y., Osborne M.P. Long-term responses of women to indole-3-carbinol or a high fiber diet. Cancer Epidemiol. Biomarkers Prev., 1994; 3(7): 591-5.
  2. Morimoto Y., Conroy S.M., Pagano I.S., Isaki M., Franke A.A., Nordt F.J., Maskarinec G. Urinary estrogen metabolites during a randomized soy trial. Nutr. Cancer. 2012; 64(2): 307-14.
  3. Киселев В.И., Ляшенко А.А. Молекулярные механизмы регуляции гиперпластических процессов. М.: Димитрейд График Групп; 2005. 346 с.
  4. Рожкова Н.И., Меских Е.В. Лечение доброкачественных заболеваний молочной железы. Опухоли репродуктивной системы. 2007; 4: 23-4.
  5. Серов В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология. М.: МЕДпресс-информ; 2008. 532 с.
  6. Идрисова Э.А., Бадгоева О.Х., Власов Р.С., Макарова И.И., Гуриев Т.Д. Сочетание гиперпролиферативных заболеваний матки и молочных желез: возможности таргентной терапии. Проблемы репродукции: Материалы IV международного конгресса по репродуктивной медицине. 2010; Спец. выпуск: 186-7.
  7. Jellinck P.H., Forkert P.G., Riddick D.S., Okey A.B., Michnovicz J.J., Bradlow H.L. Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochem. Pharmacol. 1993; 43: 1129-36.
  8. Szaefer H., Licznerska B., Krajka-Kuźniak V., Bartoszek A., Baer-Dubowska W. Modulation of CYP1A1, CYP1A2 and CYP1B1 expression by cabbage juices and indoles in human breast cell lines. Nutr. Cancer. 2012; 64(6): 879-88.
  9. Ашрафян Л.А. Опухоли репродуктивных органов (этиология и патогенез). М.: Димитрейд График Групп; 2007. 216 с.
  10. Weng J.R., Omar H.A., Kulp S.K., Chen C.S. Pharmacological exploitation of indole-3-carbinol to develop potent antitumor agents. Mini Rev. Med. Chem. 2010; 10(5): 398-404.
  11. Sarkar F.H., Li Y. Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat. Rev. 2009; 35(7): 597-607.
  12. Ahmad A., Sakr W.A., Rahman K.M. Anticancer properties of indole compounds: mechanism of apoptosis induction and role in chemotherapy. Curr. Drug Targets. 2010; 11(6): 652-66.
  13. Hong C., Firestone G.L., Bjeldanes L.F. Bcl-2 family-mediated apoptotic effects of 3,3’-diindolylmethane (DIM) in human breast cancer cells. Biochem. Pharmacol. 2002; 63(6): 1085-97.
  14. Nachshon-Kedmi M., Yannai S., Fares F.A. Induction of apoptosis in human prostate cancer cell line, PC3, by 3,3’-diindolylmethane through the mitochondrial pathway. Br. J. Cancer. 2004; 91(7): 1358-63.
  15. Matsuzaki Y., Koyama M., Hitomi T., Kawanaka M., Sakai T. Indole-3-carbinol activates the cyclin-dependent kinase inhibitor p15(INK4b) gene. FEBS Lett. 2004; 576(1-2): 137-40.
  16. Acharya A., Das I., Singh S., Saha T. Chemopreventive properties of indole-3-carbinol, diindolylmethane and other constituents of cardamom against carcinogenesis. Recent Pat. Food Nutr. Agric. 2010; 2(2): 166-77.
  17. Saw C.L., Cintrón M., Wu T.Y., Guo Y., Huang Y., Jeong W.S., Kong A.N. Pharmacodynamics of dietary phytochemical indoles I3C and DIM: Induction of Nrf2-mediated phase II drug metabolizing and antioxidant genes and synergism with isothiocyanates. Biopharm. Drug Dispos. 2011; 32(5): 289-300.
  18. Kunimasa K., Kobayashi T., Kaji K., Ohta T. Antiangiogenic effects of indole-3-carbinol and 3,3’-diindolylmethane are associated with their differential regulation of ERK1/2 and Akt in tube-forming HUVEC. J. Nutr. 2010; 140(1): 1-6.
  19. Wong G.Y., Bradlow L., Sepkovic D., Mehl S., Mailman J., Osborne M.P. Dose-ranging study of indole-3-carbinol for breast cancer prevention. J. Cell Biochem. 1997; 28-29(Suppl.): 111-6.
  20. Terry P., Wolk A., Persson I., Magnusson C. Brassica vegetables and breast cancer risk. JAMA. 2001; 285(23): 2975-7.
  21. Meng Q., Yuan F., Goldberg I.D., Rosen E.M., Auborn K., Fan S. Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells. J. Nutr. 2000; 130(12): 2927-31.
  22. Reed G.A., Peterson K.S., Smith H.J., Gray J.C., Sullivan D.K., Mayo M.S. et al. A phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol. Biomarkers Prev. 2005; 14(8): 1953-60.
  23. Reed G.A., Arneson D.W., Putnam W.C., Smith H.J., Gray J.C., Sullivan D.K. et al. Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3’-diindolylmethane. Cancer Epidemiol. Biomarkers Prev. 2006; 15(12): 2477-81.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies